Clinical Trial: Effect of Autologous Dendritic Cell Administration on Improving Neuropathy Symptoms and Inflammatory Biomarkers in Diabetic Neuropathy.

Autor:	Setiawan E; Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia.; Department of Neurology, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia., Ginting CN; Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia., Jonny J; Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia.; Faculty of Military Medicine, Indonesia Defence University, Bogor 16810, Indonesia.; Faculty of Medicine, Universitas Pembangunan Nasional 'Veteran' Jakarta, Jakarta 12450, Indonesia.; Nephrology Division, Department of Internal Medicine, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia., Hernowo BA; Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia.; Indonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia., Putranto TA; Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia.; Faculty of Medicine, Universitas Pembangunan Nasional 'Veteran' Jakarta, Jakarta 12450, Indonesia.; Indonesia Army Cellcure Center, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia.; Department of Radiology, Gatot Soebroto Army Central Hospital, Jakarta 10410, Indonesia.
Jazyk:	angličtina
Zdroj:	Current issues in molecular biology [Curr Issues Mol Biol] 2024 Dec 20; Vol. 46 (12), pp. 14366-14380. Date of Electronic Publication: 2024 Dec 20.
DOI:	10.3390/cimb46120861
Abstrakt:	Type 2 diabetes mellitus (T2DM) is a global health concern, with diabetic neuropathy (DN) being a prevalent complication. Current DN treatments focus on blood glucose control and pain management, which show limited efficacy. This study explored the effects of autologous dendritic cell (DC) administration on improving DN symptoms. A quasi-experimental clinical trial was conducted on 28 DN patients at Gatot Soebroto Army Hospital. Patients received autologous DC administration, with their Toronto Clinical Neuropathy Score (TCNS), Transforming Growth Factor-β (TGF-β), and Vascular Cell Adhesion Molecule-1 (VCAM-1) levels measured before and at four weeks after treatment. The results show an average TCNS reduction from 8.93 to 7.5 ( p < 0.001). TGF-β levels increased slightly from 41.16 ng/mL to 44.18 ng/mL ( p > 0.05). VCAM-1 levels increased from 1389.75 ng/mL to 1403.85 ng/mL. Correlation analysis showed that TGF-β levels had a significant negative correlation with the TCNS (r = -0.353; p = 0.033) and VCAM-1 levels (r = -0.521; p = 0.002). Autologous DC administration significantly improves DN. While the changes in TGF-β and VCAM-1 levels were not statistically significant, their trends suggest that there was an anti-inflammatory effect. These findings highlight the potential of autologous DC therapy as a complementary approach to manage DN through inflammation reduction and nerve repair.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu